At close: Apr 22, 5:00 PM EST
$0.3532
0.01454.28%
After Hours: 4:05 PM EST
Theriva Biologics Inc Analyst Ratings
TOVXAMEX
Theriva Biologics Analyst Ratings and Price Targets | AMEX:TOVX | Benzinga
Theriva Biologics Inc has a consensus price target of $1 based on the ratings of 1 analysts. The high is $1 issued by Maxim Group on March 31, 2026. The low is $1 issued by Maxim Group on March 31, 2026. The 2 most-recent analyst ratings were released by Maxim Group on March 31, 2026 and November 13, 2024, respectively. With an average price target of $3.5 between Maxim Group, there's an implied 890.94% upside for Theriva Biologics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Theriva Biologics
Loading calendar...
FAQ
What is the target price for Theriva Biologics (TOVX) stock?
The latest price target for Theriva Biologics (AMEX:TOVX) was reported by Maxim Group on March 31, 2026. The analyst firm set a price target for $1.00 expecting TOVX to rise to within 12 months (a possible 183.13% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Theriva Biologics (TOVX)?
The latest analyst rating for Theriva Biologics (AMEX:TOVX) was provided by Maxim Group, and Theriva Biologics upgraded their buy rating.
When was the last upgrade for Theriva Biologics (TOVX)?
The last upgrade for Theriva Biologics Inc happened on March 31, 2026 when Maxim Group raised their price target to $1. Maxim Group previously had a hold for Theriva Biologics Inc.
When was the last downgrade for Theriva Biologics (TOVX)?
The last downgrade for Theriva Biologics Inc happened on May 8, 2025 when Maxim Group changed their price target from N/A to N/A for Theriva Biologics Inc.
When is the next analyst rating going to be posted or updated for Theriva Biologics (TOVX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theriva Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theriva Biologics was filed on March 31, 2026 so you should expect the next rating to be made available sometime around March 31, 2027.
Is the Analyst Rating Theriva Biologics (TOVX) correct?
While ratings are subjective and will change, the latest Theriva Biologics (TOVX) rating was a upgraded with a price target of $0.00 to $1.00. The current price Theriva Biologics (TOVX) is trading at is $0.35, which is within the analyst’s predicted range.
